SG Americas Securities LLC Has $1.42 Million Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL

Posted by Geri Gentry on Jul 4th, 2026

SG Americas Securities LLC decreased its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 57.5% during the first quarter, HoldingsChannel reports. The firm owned 2,711 shares of the biopharmaceutical company’s stock after selling 3,675 shares during the quarter. SG Americas Securities LLC’s holdings in Madrigal Pharmaceuticals were worth $1,419,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of MDGL. Flagship Harbor Advisors LLC bought a new stake in shares of Madrigal Pharmaceuticals during the 4th quarter worth $29,000. Aventura Private Wealth LLC acquired a new position in Madrigal Pharmaceuticals in the 4th quarter valued at $36,000. Kemnay Advisory Services Inc. bought a new position in Madrigal Pharmaceuticals in the 4th quarter worth $39,000. Quarry LP bought a new position in Madrigal Pharmaceuticals in the 3rd quarter worth $39,000. Finally, Eastern Bank lifted its position in Madrigal Pharmaceuticals by 32.3% during the 4th quarter. Eastern Bank now owns 86 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 21 shares during the last quarter. 98.50% of the stock is currently owned by institutional investors and hedge funds.

Madrigal Pharmaceuticals Stock Performance

Shares of MDGL stock opened at $528.10 on Friday. Madrigal Pharmaceuticals, Inc. has a 1 year low of $284.02 and a 1 year high of $615.00. The firm’s fifty day simple moving average is $508.48 and its 200 day simple moving average is $504.35. The firm has a market capitalization of $12.18 billion, a P/E ratio of -41.26 and a beta of -1.05. The company has a current ratio of 3.50, a quick ratio of 3.16 and a debt-to-equity ratio of 0.63.

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($3.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.61) by $0.36. Madrigal Pharmaceuticals had a negative net margin of 27.32% and a negative return on equity of 50.15%. The firm had revenue of $311.34 million during the quarter, compared to the consensus estimate of $301.05 million. During the same period in the prior year, the firm earned ($3.32) EPS. The business’s revenue was up 126.8% on a year-over-year basis. As a group, sell-side analysts predict that Madrigal Pharmaceuticals, Inc. will post -7.3 EPS for the current year.

Insider Activity

In related news, insider David Soergel sold 1,042 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $495.74, for a total value of $516,561.08. Following the completion of the sale, the insider owned 10,033 shares in the company, valued at approximately $4,973,759.42. This trade represents a 9.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard S. Levy sold 5,682 shares of Madrigal Pharmaceuticals stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $515.44, for a total value of $2,928,730.08. Following the sale, the director directly owned 22,015 shares in the company, valued at approximately $11,347,411.60. This trade represents a 20.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 7,568 shares of company stock worth $3,880,711. Insiders own 17.60% of the company’s stock.

Analyst Ratings Changes

MDGL has been the subject of a number of recent analyst reports. Wells Fargo & Company upgraded shares of Madrigal Pharmaceuticals to an “overweight” rating in a report on Monday, June 1st. Evercore set a $649.00 price objective on Madrigal Pharmaceuticals in a research note on Thursday, May 7th. Piper Sandler reissued an “overweight” rating on shares of Madrigal Pharmaceuticals in a research report on Wednesday, June 24th. Canaccord Genuity Group decreased their target price on Madrigal Pharmaceuticals from $587.00 to $578.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Madrigal Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $687.93.

Check Out Our Latest Report on Madrigal Pharmaceuticals

Madrigal Pharmaceuticals Profile

(Free Report)

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.